Allergic Rhinitis Market Segmentation:
Route of Administration (Nasal & Others, Oral)
By 2035, nasal & others segment is expected to dominate over 55.3% allergic rhinitis market share. The growth is fostered by direct, local drug delivery, thus imparting a fast onset of action and greater efficacy in symptom control. For instance, in September 2022, Hikma Pharmaceuticals PLC and Glenmark Pharmaceuticals Ltd. collaboratively produced a nasal spray, Ryaltris. This is approved by the FDA and is effective for children aged between 12 years and over and acts within 15 minutes of the nasal problems. Ease of use, convenience, and relatively low-cost add to the dominance of the nasal route. Moreover, patient preference for self-administration through nasal sprays further propels higher adoption in the market.
Type (Seasonal Allergic Rhinitis, Perennial Allergic Rhinitis, Occupational Allergic Rhinitis)
The seasonal allergic rhinitis segment gains a significant proportion of the allergic rhinitis market due to the immense prevalence of pollen-related allergies, mostly during certain seasons, including spring and fall. Being seasonal, the disease causes episodic attacks resulting in a relatively frequent visit by the patients to their treating physicians, therefore supporting continuous demand in the market. For instance, in February 2024, Novartis announced that the US FDA has approved Xolair (omalizumab) for reducing allergic reactions, including anaphylaxis with IgE-mediated food allergy. Over-the-counter and prescription drugs differentiated strictly based on seasonal symptoms enhance the dominance of the segment.
Our in-depth analysis of the allergic rhinitis market includes the following segments:
|
Route of Administration |
|
|
Treatment |
|
|
Type |
|
